Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD4547 plus non-steroidal aromatase inhibitor in ER-positive breast cancer progressing on anastrozole/letrozole
2011-000454-32Phase 2Completed
- Sponsor
- Imperial College London
- Start
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fexagratinib in estrogen receptor-positive breast cancer, sponsored by Imperial College London. Primary endpoint: Safety and tolerability of AZD4547 in combination with anastrozole or letrozole (safety run-in). Started Jan 2012; status: completed.
02
Drugs
fexagratinib
03
Conditions
estrogen receptor-positive breast cancer
Beyond the preview
Go deeper on 2011-000454-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000454-32.